Home BioMap Launches AI Drug Safety Evaluation System, Exploring 'Virtual Monkeys' for Virtual Dosing Amid Recent Prospectus Filing

BioMap Launches AI Drug Safety Evaluation System, Exploring 'Virtual Monkeys' for Virtual Dosing Amid Recent Prospectus Filing

Nov 19, 2026 14:54 CST Updated 14:54
BioMap

Developer of Innovative Drug R&D Platform

Stock trading depends onGolden Kirin Analyst Research Report, authoritative, professional, timely, and comprehensive, helping you uncover potential thematic opportunities!

(Source: Jiemian News)

On November 19, BioMap officially launched its AI-driven drug safety evaluation system, integrating virtual cell models, toxicity prediction capabilities, and non-clinical safety assessment services. Leveraging safety prediction models such as the “Virtual Monkey,” the system extends AI-based predictions from the cellular level to in vivo animal contexts. According to the company, BioMap is combining existing animal trial data to explore virtual dosing through safety prediction models like the “Virtual Monkey.”